Brief: Timber Pharmaceuticals Receives Orphan Drug Designation From U.S. FDA For Tmb-003 For The Treatment Of Systemic Sclerosis
12/01/2021 21:28
Jan 12 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION
FROM
U.S. FDA FOR TMB-003 FOR THE TREATMENT OF SYSTEMIC SCLEROSIS
* TIMBER PHARMACEUTICALS INC - EXPECTS TO SUBMIT
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION TO FDA IN 2022 FOR TMB-003
Source text for Eikon: ID:nGNXQMXbB
Further company coverage: TMBR.A
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing